The statements below are Merchant Law Group’s account of this case. They reflect allegations or the firm’s position and have not been determined by a court unless a settlement or judgment is noted.
Settlement Update
2026 Update: Merchant Law Group LLP is pleased to announce that a Canada-wide Class Action Settlement has been approved regarding the Xarelto Class Action. All Canadian residents who properly qualify under the Settlement are entitled to seek compensation, before the claims deadline. The compensation process has begun — and you may reach our law firm at xarelto@merchantlaw.com or 1-403-219-0178 with any questions or to receive a free consultation with one of our lawyers, about your potential compensation options under this Canadian class action settlement. [Please note, all Canadian residents are entitled to the same compensation and apply to the same settlement fund, regardless of their province of residence. Please read the Official Notice at the bottom of this page for more details.]
Source: Merchant Law Group
About This Case
The Proceedings raised various allegations against the Defendants and sought damages on behalf of all Canadians for harm and injuries which were allegedly related to the use of Xarelto®. The settlement of the Proceedings (the “ Settlement ”) has been approved by the Courts.
Source: Merchant Law Group
Who May Be Eligible
The Settlement applies to the following Class Members: Canadian residents, excluding residents of Québec, who were prescribed and ingested Xarelto® in Canada (“Primary Class Member”) before October 27, 2025 , and individuals who may make a claim pursuant to Family Compensation Legislation because of their relationship with a Primary Class Member (“Family Class Member”) (the “ Saskatchewan Class ”); and All persons residing in Québec who were prescribed and have ingested the drug Xarelto® (rivaroxaban) from January 1, 2008 to October 27, 2025 , and their successors, assigns, family members, and dependents (the “ Québec Class ”).
Source: Merchant Law Group
How to Register
If you are a Class Member as defined by the above-referenced settlement, you may be eligible for financial compensation if [on or before the claims deadline of February 17, 2027] you submit a Claim Form with supporting medical, pharmaceutical, or other documentation that establishes that you [or a family member] was prescribed Xarelto® in Canada before October 27, 2025, where the Primary Claimant : a) experienced a bleeding event that led to the Primary Claimant’s – death, or – resulted in a brain injury, or – other significant organ damage with long-term cognitive or physical impairment, or – required at least 24 hours of hospitalization; and b) used Xarelto® within 24 hours before experiencing the bleeding event . Supporting documentation to establish the prescription and use of Xarelto® includes medical, pharmacy, and other records that Xarelto® (or before November 2023, rivaroxaban) was prescribed and dispensed by a pharmacy to the Primary Claimant. [As more fully described in the Compensation Protocol under this class action settlement, in some cases, a statement by a Primary Claimant or his/her physician may suffice to establish the prescription and use of Xarelto®.]
Source: Merchant Law Group
Disclaimer: This information is sourced from Merchant Law Group. It is provided for general information only and does not constitute legal advice. Always verify details with the original source before taking any action.
Legal disclaimer: Information on this page is general in nature and does not constitute legal advice. ClaimBar tracks class action settlements and provides updates. Always seek professional legal advice for your specific circumstances.
Did this page answer your question?